![Figure 2. ICOS-/- donor T cells cause significantly less GVHD mortality and morbidity in allo-HSCT recipients. (A-C) Parent→F1 model. C3FeB6F1 mice were lethally irradiated (1300 cGy split) and received transplants with TCD allo-HSCs from WT B6 mice (5 × 106) and 1 × 106 WT or ICOS-/- B6 T cells. (D-F) MHC class I and II disparate model. BALB/c recipients were lethally irradiated (900 cGy split) and received transplants with TCD allo-HSCs from WT B6 mouse bone marrow (5 × 106) and splenic WT or ICOS-/- B6 T cells (0.5 × 106). Panels A and D represent survival curves; B and E, weight loss curves; and C and F, clinical GVHD scores. BM-only control groups (n = 0 to 4) and T-cell recipient groups (n = 16 to 20) are derived from 2 combined experiments. Allo-HSC control group (\batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \({\odot}\) \end{document}), WT allo-HSCs + WT T-cell recipients (▪), and WT allo-HSCs + ICOS-/- T-cell recipients (▵). Statistical analyses shown in all graphics represent recipients of WT versus ICOS-/- T-cell recipients.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/106/9/10.1182_blood-2005-01-0410/6/zh80210586430002.jpeg?Expires=1735839987&Signature=T18cRcmsmzSIIwnuZs3IddWiOd2iPsbHOCVAQCaYA~7qKjAMtuaXBqEaMQEw0nsOhd5dBvgR3s8DNu6a8X5L4QGTRGL2X2469tCCdN8kHSUu5Ty0jvAOj555oeY6WZekGiMtWt3vp~yGcLe8WWwLpmP2gW6XNeRnsmvoaO2UD61tw3w0ywENLihCDyu50D1LOV3n~D76GCxNsEa~d9ZK9yO8lv2wOLu1sxZBr8vRP26YnnECwc8TyET5C7D0UAqaAyZpOXK-BmZ5wA4C7IXgMjHov~tl6u0-VhY5vuvz3hvYgonb6uXo2L7BZnI~6eEIJcvKuuuh~ORNxK0yCPkw9w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
ICOS-/- donor T cells cause significantly less GVHD mortality and morbidity in allo-HSCT recipients. (A-C) Parent→F1 model. C3FeB6F1 mice were lethally irradiated (1300 cGy split) and received transplants with TCD allo-HSCs from WT B6 mice (5 × 106) and 1 × 106 WT or ICOS-/- B6 T cells. (D-F) MHC class I and II disparate model. BALB/c recipients were lethally irradiated (900 cGy split) and received transplants with TCD allo-HSCs from WT B6 mouse bone marrow (5 × 106) and splenic WT or ICOS-/- B6 T cells (0.5 × 106). Panels A and D represent survival curves; B and E, weight loss curves; and C and F, clinical GVHD scores. BM-only control groups (n = 0 to 4) and T-cell recipient groups (n = 16 to 20) are derived from 2 combined experiments. Allo-HSC control group (
